The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery-Reference-Cited by-同舟云学术

The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery

Published:2021-03-10 Issue:3 Volume:156 Page:e206363
ISSN:2168-6254
Container-title:JAMA Surgery
language:en
Short-container-title:JAMA Surg

Author:

Kusamura Shigeki¹,Barretta Francesco²,Yonemura Yutaka³,Sugarbaker Paul Hendrick⁴,Moran Brendan John⁵,Levine Edward A.⁶,Goere Diane⁷,Baratti Dario¹,Nizri Eran¹⁸,Morris David Lawson⁹,Glehen Olivier¹⁰,Sardi Armando¹¹,Barrios Pedro¹²,Quénet François¹³,Villeneuve Laurent¹⁴,Gómez-Portilla Alberto¹⁵¹⁶¹⁷,de Hingh Ignace¹⁸,Ceelen Wim¹⁹,Pelz Joerg O. W.²⁰,Piso Pompiliu²¹,González-Moreno Santiago²²,Van Der Speeten Kurt²³,Deraco Marcello¹,

Affiliation:

1. Peritoneal Surface Malignancies Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori dei Tumori di Milano, Milano, Italy

2. Clinical Epidemiology and Trial Organization Unit, Fondazione IRCCS Istituto Nazionale Tumori dei Tumori di Milano, Milano, Italy

3. Nonprofit Organization to Support Peritoneal Surface Malignancy Treatment, Kishiwada, Japan

4. Washington Cancer Institute, Washington Hospital Center, Washington, DC

5. Basingstoke and North Hampshire National Health Service Foundation Trust, Basingstoke, United Kingdom

6. Surgical Oncology Service, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina

7. Department of Visceral and Oncologic Surgery, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Paris, France

8. fellow at European School of Peritoneal Surface Oncology, Milano, Italy

9. Hepatobiliary and Surgical Oncology Unit, Department of Surgery, University of New South Wales, St George Hospital, Sydney, Australia

10. Department of Digestive Surgery, Centre Hospitalo-Universitaire Lyon-Sud, Hospices Civils de Lyon, Lyon, France

11. Division of Surgery, Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, Maryland

12. Department of Oncological Surgery, Hospital Sant Joan Despí, Moises Broggi, Peritoneal Surface Malignancy Catalonian’s Programme, Sant Joan Despí, Barcelona, Spain

13. Centre Régional de Lutte Contre le Cancer Val d’Aurell, Montpellier, France

14. Réseau National de Prise en Charge des Tumeurs Rares du Péritoine, French National Registry of Rare Peritoneal Surface Malignancies, Lyon, France

15. Department of General Surgery, Hospital Universitario de Araba, Hospital Universitario Araba Sede Hospital Santiago, Santiago, Spain

16. Departamento de Cirugía General, Universidad del País Vasco, Vitoria, Spain

17. Programa de Carcinomatosis Peritoneal, Hospital San José, Vitoria, Spain

18. Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

19. Department of Gastrointestinal Surgery, Ghent University Hospital, Ghent, Belgium

20. Department of Surgery I, University of Wuerzburg, Wuerzburg, Germany

21. Department of General and Visceral Surgery, Krankenhaus Barmherzige Brüder, Regensburg, Germany

22. Peritoneal Surface Oncology Program, Department of Surgical Oncology, MD Anderson Cancer Center, Madrid, Spain

23. Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Genk, Belgium

Publisher

American Medical Association (AMA)

Subject

Surgery

Link

https://jamanetwork.com/journals/jamasurgery/articlepdf/2775621/jamasurgery_kusamura_2021_oi_200097_1614638734.23894.pdf

Reference40 articles.

1. The etiology, clinical presentation, and management of pseudomyxoma peritonei.;Moran;Surg Oncol Clin N Am,2003

2. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix: a clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors.;Carr;Cancer,1995

3. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?;Sugarbaker;Lancet Oncol,2006

4. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach.;Sugarbaker;Expert Opin Pharmacother,2009

5. Hyperthermic intraperitoneal chemotherapy in ovarian cancer.;van Driel;N Engl J Med,2018

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncological outcomes and hospitalization cost of hyperthermic intraperitoneal chemotherapy (HIPEC) open and closed abdomen techniques: Results from two French expert centers;European Journal of Surgical Oncology;2024-02

2. Peritoneal mesothelioma and pseudomyxoma peritonei;best practice onkologie;2024-01-22

3. Laparoscopic Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis: Improved Short-term Outcomes Revealed Through Propensity Score Matching Analysis;Journal of Gastrointestinal Cancer;2024-01-15

4. Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma;Cancers;2024-01-15

5. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China;Orphanet Journal of Rare Diseases;2024-01-04